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Abstract
The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but
its impact on therapy response is still under controversial debate. Here we wanted to test if EGFRvIII influences the
sensitivity towards the alkylating agent temozolomide (TMZ). Therefore, we retrospectively analyzed the survival of 336
GBM patients, demonstrating that under standard treatment, which includes TMZ, EGFRvIII expression is associated with
prolonged survival, but only in patients with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylated
tumors. Using isogenic GBM cell lines with endogenous EGFRvIII expression we could demonstrate that EGFRvIII
increases TMZ sensitivity and results in enhanced numbers of DNA double-strand breaks and a pronounced S/G2-phase
arrest after TMZ treatment. We observed a higher expression of DNA mismatch repair (MMR) proteins in EGFRvIII+ cells
and patient tumor samples, which was most pronounced for MSH2 and MSH6. EGFRvIII-specific knockdown reduced
MMR protein expression thereby increasing TMZ resistance. Subsequent functional kinome profiling revealed an increased
activation of p38- and ERK1/2-dependent signaling in EGFRvIII expressing cells, which regulates MMR protein expression
downstream of EGFRvIII. In summary, our results demonstrate that the oncoprotein EGFRvIII sensitizes a fraction of GBM
to current standard of care treatment through the upregulation of DNA MMR.
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Introduction
Glioblastoma (GBM, glioma WHO grade IV) is the most
common malignant brain tumor in humans. Despite intense
treatment including surgery, radio- and chemotherapy the
median overall survival time of patients with GBM is less
than two years, with huge variations between different
subtypes [1, 2]. GBM are characterized by diverse genetic
alterations, such as mutations in the isocitrate dehy-
drogenase (IDH) 1 or 2 genes, methylation of the O6-
methylguanine-DNA methyltransferase (MGMT) promoter,
the amplification of the gene encoding the epidermal growth
factor receptor (EGFR) or the expression of the EGFR
variant III (EGFRvIII). While it is well accepted that IDH
status and MGMT promoter status have prognostic sig-
nificance in predicting patient survival after standard ther-
apy [3–5], the influence of EGFR amplification and
EGFRvIII expression on patient survival is still under
controversial debate. To address this issue we performed a
retrospective survival analysis of GBM patients with known
IDH, MGMT and EGFR/EGFRvIII status, who had been
treated with surgery, irradiation and TMZ.
The EGFRvIII is caused by an in-frame deletion of
EGFR exons 2–7. It is predominantly associated with an
EGFR amplification and is expressed in approximately one-
third of all primary GBM [6, 7]. It is localized in clusters
within the cellular membrane [8] and shows constitutive
tyrosine kinase activity causing an upregulation of pro-
survival downstream signaling pathways, such as PI3K/
AKT and STAT3 signaling [9, 10]. The EGFRvIII is
accepted to be an oncogene and its expression is therefore
assumed to have a negative impact on treatment outcome of
GBM patients [11–13]. However, clinical studies have so
far failed to prove that EGFRvIII is a reliable prognostic
marker: while in smaller studies EGFRvIII expression was
found to be associated with either better or worse survival,
larger studies did not observe any predictive or prognostic
impact of EGFRvIII expression [12, 14–19]. A summary of
the relevant literature is given in supplementary Table S1
(Table S1). In a previous study using isogenic GBM cells
with differences in endogenous EGFRvIII expression we
had demonstrated that EGFRvIII has no impact on cellular
radiosensitivity [20]. These results are supported by clinical
studies of GBM patients treated with adjuvant radiotherapy
only [21, 22]. However, today’s standard therapy also
includes concurrent TMZ treatment. Because there is no
correlation of radiosensitivity and TMZ sensitivity [23],
these previous studies do not indicate whether EGFRvIII
influences TMZ sensitivity or not. Yet, due to the recent and
ongoing development and clinical assessment of various
EGFR and EGFRvIII-targeting strategies, such as peptide-
based vaccines (rindopepimut), monoclonal antibody
immunotoxin conjugates (ABT-414) or EGFRvIII-specific
chimeric antigen receptor (CAR) T cells a deeper under-
standing of the molecular biology and clinical relevance of
EGFR amplification and EGFRvIII in GBM is definitely
required [24–27].
Here we analyzed if EGFRvIII has an impact on TMZ
sensitivity in GBM patients treated with radiotherapy and
TMZ. We show here that EGFRvIII expression is specifi-
cally associated with prolonged survival, but only if the
tumors were MGMT promoter methylated. In line with the
clinical observation, we observe increased TMZ sensitivity
of EGFRvIII expressing and MGMT promoter methylated
GBM cells in vitro and in vivo. The increased TMZ sen-
sitivity could be linked to an increased MMR protein
expression and therefore upregulated MMR in EGFRvIII+
cells and tumors.
Regarding cellular signaling, our data show that the
increased expression of MMR proteins is mediated by p38
and ERK1/2 downstream of EGFRvIII. These data
demonstrate that the oncoprotein EGFRvIII does not med-
iate resistance but confers sensitivity towards current GBM
chemotherapy with TMZ. We, therefore, identified EGFR-
vIII as a prognostic biomarker, which may point towards an
Achilles´ heel in a subset of GBM, warranting further pre-
clinical and clinical studies.
Results
EGFRvIII expression is associated with better
response to standard of care treatment
To test if EGFRvIII has an influence on TMZ sensitivity we
retrospectively analyzed the overall survival of 336 patients
with IDH1 wild type (wt) GBM and known MGMT pro-
moter, EGFR amplification and EGFRvIIII status who had
been treated with standard of care. Patients from three dif-
ferent cohorts were included, namely the UPenn cohort
[28], the Bristol cohort [18] and the TCGA cohort [29]
(Table S2). We initially fitted a univariate cox proportional
hazards model to include the variables of EGFRvIII status,
EGFR amplification status, MGMT promoter methylation
status, gender and age. As expected, we observed a sig-
nificant association with survival for MGMT promoter
methylation status (Fig. 1a; hazard ratio [HR]= 0.52; 95%
CI= 0.39–0.68; p < 0.0001), and age (Fig. S1; HR= 1.02;
95% CI= 1.01–1.04; p= 0.002), demonstrating shorter
survival for elderly patients. We also detected an association
with EGFRvIII status that was significant, albeit at the 10%
level (Fig. 1b; HR= 0.75; 95% CI= 0.56–1.02; p= 0.06).
Using multivariate models including these three variables
we observed that age and MGMT promoter methylation
status increased in significance with the same HRs, 95% CIs
and p-values < 0.05. However, the strength of association
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for EGFRvIII decreased (HR= 0.78; 95% CI= 0.58–1.06;
p= 0.11). Additional pairwise models indicated that this
was owing to an interaction between EGFRvIII and MGMT
promoter methylation status, so we proceeded to examine
the effect of EGFRvIII in patients stratified as MGMT
promoter unmethylated (MGMT-U) and MGMT promoter
methylated (MGMT-M) separately. In MGMT-U patients,
the EGFRvIII status had no impact on patient survival (Fig. 1c;
Fig. S2). For patients with MGMT-M tumors, however,
EGFRvIII positivity was associated with a median survival
benefit of 6 month (791 days vs. 608 days) when compared
to the survival of patients with EGFRvIII negative
(EGFRvIII-) tumors (Fig. 1d, Fig. S2). Since EGFRvIII
expression is associated with EGFR amplification [16, 30]
(Table S2), we also analyzed the effect of EGFRvIII-
positivity solely in patients with MGMT-M and EGFRampl
tumors. Here, EGFRvIII-positivity was also associated with
a favorable outcome (542 days vs. 791 days), with the
difference reaching statistical significance (Fig. 1e, Fig. S3;
p= 0.02) (Fig. 1e; Fig. S3). The beneficial impact of
EGFRvIII even remained when analyzing EGFRampl
patients irrespective of their MGMT status, which further
underpins the findings, that EGFRvIII and not EGFR
amplification is associated with prolonged survival (Fig. S4).
According to this retrospective clinical data set, which
includes MGMT-, EGFR- and EGFRvIII-status, EGFRvIII
positivity but not EGFR amplification is a positive predictor
of response to standard of care first line treatment inMGMT-
M GBM patients.
EGFRvIII increases cellular TMZ sensitivity
The clinical data indicate an increased sensitivity of EGFRvIII
+ GBM cells towards TMZ. We, therefore, tested the impact
of EGFRvIII expression on cellular treatment response by
using two pairs of isogenic cell lines with (EGFRvIII+) and
without (EGFRvIII−) endogenous EGFRvIII expression
(Fig. 2a–c) which were established from parental DKMG and
BS153 cell lines as described previously [20]. Importantly,
neither cell line expressed MGMT (Fig. 2c) due to MGMT
promoter methylation (Fig. 2d) and MGMT expression was
not induced by TMZ treatment (Fig. S5).
a all patients b                        all patients
c                     MGMT-U d MGMT-M                            e                EGFRampl./MGMT-M
Fig. 1 Overall survival according to EGFRvIII, MGMT promoter
methylation and EGFRampl. status. Kaplan–Meier estimates of
EGFRvIII−/+GBM patients treated with standard of care. a Entire
cohort stratified for EGFRvIII status. b Entire cohort stratified for
MGMT promoter methylation status. c MGMT-U patients stratified for
EGFRvIII status. d MGMT-M patients stratified for EGFRvIII status.
e EGFRampl./MGMT-M patients stratified for EGFRvIII status.
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Analyzing the proliferation of the EGFRvIII+ and
EGFRvIII− sub-cell lines under treatment with clinically
relevant TMZ concentrations [31], we observed inhibited
cell growth in all cultures (Fig. 2e). There was no difference
detectable for the EGFRvIII+ and EGFRvIII- sub-cell lines
derived from DKMG (Fig. 2e, f), but for those originating
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from BS153, EGFRvIII+ cells showed stronger inhibition
(Fig. 2e, f). Colony formation assays offer a more stringent
analysis of cellular cytotoxicity and here, we indeed
observed significant differences for both, the DKMG and
BS153 sub-cell lines with EGFRvIII+ cells demonstrating a
clear and significant reduction in survival after TMZ treat-
ment (Fig. 2g). Partial knockdown of EGFRvIII in
BS153vIII+ cells restored TMZ resistance, confirming that
EGFRvIII expression is responsible for increased TMZ
sensitivity (Fig. 2h). Furthermore, we tested whether
EGFRvIII expression caused increased TMZ sensitivity
in vivo, using orthotopic BS153vIII−/+ xenograft tumors
grown from BS153 cell cultures with over 90% EGFRvIII
positivity and negativity, respectively (Fig. S6). While we
observed no significant difference in survival between the
untreated BS153vIII− and BS153vIII+ control groups
(Fig. S7), TMZ treatment significantly prolonged survival
for EGFRvIII+ (44 d vs. 61.5 d) but not EGFRvIII− mice
(50 d vs. 45.5; Fig. 4i). Together, these data clearly show
that EGFRvIII expression is associated with cellular TMZ
sensitivity, which is further demonstrated by improved
tumor response in vivo.
EGFRvIII increases DNA damage after TMZ
treatment due to upregulated MMR
Analysis of Annexin V positive cells as a marker for
apoptosis revealed no difference between EGFRvIII− and
EGFRvIII+ BS153 cells although 20 µM TMZ induced
apoptosis in a fraction of cells (Fig. 3a, b). This demon-
strates that increased inactivation of EGFRvIII+ cells after
20 µM TMZ treatment is caused by apoptosis-independent
mechanisms.
When analyzing the cell cycle distribution we detected
an increase in the fraction of S/G2-phase cells for the
EGFRvIII+ sub-cell lines (Fig. 3c, d, Fig. S8), which was
more pronounced for the BS153 cells. Since such an S/G2-
arrest often indicates accumulation of DNA damage and
increased replication stress we analyzed the DNA double-
strand break (DSB) marker proteins γH2AX and 53BP1
after TMZ treatment. In both EGFRvIII+ cell lines we
observed an increase in the number of γH2AX/53BP1
double-positive foci after TMZ treatment compared to
their EGFRvIII− counterparts, demonstrating more TMZ-
induced DSB (Fig. 3e, f).
TMZ induces DSB by a futile MMR cycle: if TMZ-
induced O6meG cannot be repaired by MGMT, MMR
removes the incorrectly paired thymidine, leading to the
accumulation of DSB during replication [32, 33]. Therefore,
enhanced MMR activity leads to an increase in TMZ-
induced DSB, resulting in increased cellular sensitivity
towards TMZ and other alkylating agents [34–39]. Since
MMR activity, and thereby TMZ sensitivity, can be regu-
lated by the level of MMR protein expression [37], we next
analyzed MMR protein expression in EGFRvIII+ and
EGFRvIII− cells in detail. First, we confirmed the impor-
tance of MMR protein expression for TMZ sensitivity in
DKMGvIII+ and BS153vIII+ cells by partially knocking
down the key MMR proteins MLH1 and MSH6 (Fig. 4a).
As expected, cells became TMZ resistant if the expression
of MLH1 or MSH6 was reduced. Even a moderate 20–60%
reduction in protein expression was sufficient to confer a
pronounced TMZ resistance, which is in line with the
observation of McFaline-Figueroa et al. [37]. Overall, the
downregulation of MLH1 and MSH6 was more efficient in
BS153vIII+ compared to DKMGvIII+ cells, leading to
almost complete TMZ resistance in these cells. These data
demonstrate that endogenous EGFRvIII expression speci-
fically sensitizes MGMT deficient cells to TMZ treatment
by upregulating MMR.
When analyzing the expression of MMR proteins in
EGFRvIII− and EGFRvIII+ cells we observed an elevated
expression of MMR proteins in both EGFRvIII+ cell lines,
which was statistically significant for MSH2, MSH3, and
MSH6 in DKMGvIII+ and for all detected MMR proteins
in BS153vIII+ (Fig. 4b). Vice versa, siRNA-mediated
downregulation of EGFRvIII in BS153vIII+ cells resulted
in a significant decrease in MMR protein expression as
measured 72 h after siRNA treatment (Fig. 4c).
To further validate these findings we assessed MSH2 and
MSH6 expression in situ using samples from three indivi-
dual GBM patients, each displaying heterogonous
Fig. 2 TMZ sensitivity of EGFRvIII−/+ GBM cells and experi-
mental tumors. DKMGvIII−/+ and BS153vIII−/+ human GBM cell
lines were used for further analysis. a EGFRvIII-specific immuno-
fluorescence staining (red). Cell nuclei were counterstained with
DAPI. b EGFRvIII expression was detected by flow cytometry using
an EGFRvIII-specific antibody (L8A4). A secondary antibody control
was used to assess unspecific staining. c Detection of EGFR, EGFR-
vIII, and MGMT by western blot analysis. MGMT expressing Jurkat
cells (JC) served as a positive and β-actin as loading control. d Ana-
lysis of MGMT promoter methylation by PCR. M1, and M2 delineate
reactions with methylation-specific primers, U1 with primers for
unmethylated DNA. e Analysis of proliferation. DKMGvIII−/+ and
BS153vIII−/+ cells were treated 24 h after seeding with 20 µM TMZ.
Cell number was determined up to 8 days (mean with S.E.M, n
= 5). f Cell growth after 7 days of TMZ treatment. DMSO served as
control. The mean value of treated cells was normalized to the mean
value of untreated cells (mean with S.E.M, n= 5; P-values are
obtained by two-tailed Student’s t test, *p < 0.05, **p < 0.01). g Sur-
vival of DKMGvIII−/+ and BS153vIII−/+ cells after TMZ treatment
assessed by colony forming assay (mean with S.E.M, n= 4; P-values
are obtained by two-tailed Student’s t test, *p < 0.05, **p < 0.01, ***p
< 0.001). h Relative cell survival of BS153vIII+ after siRNA-
mediated EGFRvIII knockdown. An siRNA against cyclophilin B
served as a control (mean with S.E.M, n= 4; one-tailed Student’s t test
was, *p < 0.05, **p < 0.01, ***p < 0.001). i Xenograft tumor response
to TMZ. Two weeks after the intracranial injection of 2.5 × 105
BS153vIII−/+ cells the mice were treated with 5 mg/kg/d TMZ or
solvent for five days. Graph: Kaplan–Meier estimates of survival.
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EGFRvIII expression. The samples were randomly chosen
from an independent cohort. We observed indeed a pro-
nounced difference between EGFRvIII− and EGFRvIII+
areas. MSH2 and MSH6 expression were clearly upregu-
lated in EGFRvIII+ areas, thereby corroborating our
in vitro findings (Fig. 4d, e).
Taken together, these data strongly suggest that endo-
genous EGFRvIII expression specifically sensitizes MGMT-
deficient cells to TMZ treatment by upregulating MMR.
EGFRvIII regulates MMR protein expression via
MAPK-signaling
As reported earlier, EGFRvIII+ cells display increased
activation of ERK1/2-dependent MAPK signaling (Fig. 5a)
[20]. We next analyzed, whether increased MAPK signaling
is involved in the upregulation of MMR. Indeed, a partial
knockdown of ERK1/2 resulted in a downregulation of
MLH1 and MSH2 but not MSH6 (Fig. 5b), which was also
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significantly upregulated in both EGFRvIII+ sub-cell lines
(Fig. 4b). To identify additional serine/threonine kinase-
dependent downstream pathways involved in EGFRvIII
signaling, we performed functional kinomic profiling of
BS153vIII−/+ cells using a peptide based in vitro assay
(Fig. 5c) [40]. The heat map in Fig. 5d shows increased
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phosphorylation of several peptides if the arrays were incu-
bated with lysates from EGFRvIII+ cells, which reached
significance for 25 peptides (Fig. 5e). The upstream kinase
analysis confirmed the increased activation of ERK1/2 and
identified additional upregulated MAP-kinases, such as p38,
JNK and ERK5 (Fig. 5f). We could not verify upregulated
ERK5 activity (data not shown) while phosphorylation of JNK
was only increased in BS153vIII+ but not in DKMGvIII+
cells as detected by western blot (Fig. 5g, h). In contrast, we
observed increased p38 phosphorylation in both EGFRvIII+
sub-cell lines. A partial siRNA mediated knockdown of p38
resulted in downregulation of all three MMR proteins, MLH1,
MSH2, and MSH6 in BS153vIII+ cells (Fig. 5i), demon-
strating that besides the ERK1/2-dependent MAPK pathway,
also the p38-dependent MAPK pathway is involved in the
EGFRvIII mediated upregulation of MMR proteins.
In summary, we propose a model, according to which
EGFRvIII expression leads to increased TMZ sensitivity in
MGMT promoter methylated cells through the upregulation
of MMR proteins via the ERK1/2 and p38 pathways
(Fig. 6). These findings offer an explanation for the
observed better prognosis of EGFRvIII+ GBM patients
carrying MGMT promoter methylation.
Discussion
EGFRvIII is an oncogene, which is expressed in about 30%
of all GBM. Although multiple clinical studies have
addressed the prognostic relevance of EGFRvIII, the impact
of EGFRvIII expression on treatment response and there-
fore patient survival is still under controversial debate. We
show here that EGFRvIII expression leads to increased
TMZ sensitivity in MGMT promoter methylated GBM,
which strongly indicates an upregulated MMR. If expres-
sed, MGMT removes the O6-alkylguanine DNA adduct
through covalent transfer of the alkyl group to the con-
served active site, thereby restoring the guanine to its nor-
mal form. In the absence of MGMT, TMZ-induced O6-
methylguanine pairs with thymine, leading to a futile MMR
repair cycle which ends up in the induction of highly toxic
DNA DSB during replication [32, 33, 39]. Therefore, MMR
activity determines the sensitivity towards TMZ and other
alkylating agents [35, 37, 38], while the level of MMR
activity is limited by the expression level of the MMR
proteins [41].
In line with that model, we detected increased MMR
protein expression in EGFRvIII+ cells and human tumor
samples (Fig. 4d, e) demonstrating increased MMR to be
the reason for the increased TMZ sensitivity in MGMT-
deficient cells and tumors. As expected, the upregulation of
MMR protein expression in EGFRvIII+ cells was accom-
panied by an increase in DSB formation (Fig. 3f). Already
small changes in the expression of single MMR proteins
had a strong influence on TMZ sensitivity, as demonstrated
by partial knockdown experiments (Fig. 4a). This is in line
with other studies, which also demonstrated that already
moderately altered MMR protein levels can have a pro-
found impact on TMZ sensitivity [37]. This sensitivity of
MMR activity towards small changes in the expression of
MMR proteins can be explained by the fact that MMR
proteins interact pairwise in a 1:1 stoichiometry [37].
Therefore, the least abundant protein determines MMR
activity, whereas changes in abundant proteins such as
PMS2 (Fig. 4b, c) will hardly be of consequence.
The clinical relevance of this interrelation is underpinned
by a study by Felsberg et al. who observed frequent
decreases in MMR protein expression in recurrent GBM
samples after TMZ treatment relative to their primary
tumors [42]. Besides, Yip et al. observed that MSH6
mutations arise in certain GBM under TMZ treatment,
leading to TMZ resistance [43]. These data and the data
presented here indicate that MMR deficiency and changes
in MMR protein expression in GBM are of greater rele-
vance than hitherto assumed.
The increased TMZ sensitivity, which we observed using
our isogenic and endogenous EGFRvIII model system, is
consistent with previous studies using EGFRvIII+ neuro-
spheres or transfected U87MG cells [15, 44]. Together with
our results, showing a profound increase in MMR protein
expression in EGFRvIII+ areas of human GBM, all these
data strongly indicate elevated MMR to be the cause
Fig. 4 MMR protein expression in vitro and in situ. a Impact of
siRNA-mediated reduction of MMR protein expression in DKMGvIII
+ and BS153vIII+ cells. Upper Western blots: Confirmation of MLH1
and MSH6 knockdown. Bottom: Clonogenic survival after TMZ
treatment. An siRNA against cyclophilin B served as a control. (mean
with S.E.M, n= 3; P values are obtained by one-tailed Student’s t test,
*p < 0.05, **p < 0.01, ***p < 0.001). b Expression of MMR proteins
and PCNA in DKMGvIII−/+ and BS153vIII−/+ cells. For western
blot analysis, samples were normalized to cell number. β-actin served
as loading control. For quantification of MMR protein and PCNA
expression the relative expression values of EGFRvIII+ cells were
normalized to the relative values of EGFRvIII- cells (mean with S.E.
M, n= 3; P-values are obtained by one-tailed Student’s t test, *p <
0.05, **p < 0.01). c Impact of siRNA-mediated EGFRvIII knockdown
in BS153vIII+ cells on MLH1, MSH2, and MSH6 expression after 24,
48, and 72 h. An siRNA against cyclophilin B served as a control.
Western blot analysis, β-actin served as a control. For quantification of
relative MMR protein expression protein levels were normalized to
β-actin and to MLH1, MSH2, and MSH6 levels in the control (mean
with S.E.M, n= 5; P-values are obtained by one-tailed Student’s t test,
*p < 0.05, **p < 0.01). d Immunohistochemical detection of EGFR-
vIII, MSH2 und MSH6 expression in one representative GBM patient
sample (GBM1) displaying heterogeneous EGFRvIII expression.
Scale bars represent 50 and 5000 µm (overview in the middle).
e Immunohistochemical detection of EGFRvIII, MSH2 und MSH6
expression in three GBM patient samples displaying heterogeneous
EGFRvIII expression. EGFRvIII− negative areas are depicted on the
left, EGFRvIII+ on the right. Scale bars represent 50 µm.
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of the improved survival of MGMT-M/EGFRvIII+ patients
observed in our retrospective analysis. Further, we could
identify the ERK1/2-dependent and the p38-dependent
MAPK pathways as regulators of MMR expression in
both EGFRvIII+ sub-cell lines (Fig. 5). This is likely due to
increased transcription, since MMR genes are regulated by
MAPK-dependent transcription factors such as AP1 or SP1
[45, 46]. It is important to state that this upregulation of
MAPK was detected in the EGFRvIII+ cells by comparing
them to the EGFRvIII− but still EGFR amplified (data not
shown) sub-cell lines, demonstrating an EGFRvIII specific
activation. Whether other downstream pathways also
influence MMR needs to be analyzed in future studies.
However, functional kinomics data already hint towards
additional MAP kinases, such as JNK and ERK5, although
subsequent validation demonstrates that these might not be
of relevance in all, but maybe only in individual EGFRvIII
expressing GBM (data not shown).
The finding that EGFRvIII+ patients treated with stan-
dard of care have a better prognosis compared to EGFRvIII
− patients (Fig. 1d, e) agrees with some but also contradicts
other studies on the prognostic impact of EGFRvIII
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(Table S1). Our analysis reveals that it is important to
includeMGMT status to identify the impact of EGFRvIII on
therapy outcome: MGMT-M/EGFRvIII+ GBM patients
showed the most favorable survival after standard of care
treatment (Fig. 1d, e). Our data are supported by at least the
following studies: (i) Montano et al. had also reported a
favorable prognosis for EGFRvIII+ and MGMT-M patients
[15]; (ii) van den Bent et al. observed that approximately
one-half of the tumors originally expressing EGFRvIII at
initial diagnosis had lost their EGFRvIII expression at
tumor recurrence after standard of care treatment [30]; (iii)
Weller et al. reported an unexpected long survival of
EGFRvIII+ patients in the ACTIV trial. While this finding
might in principle also be explained by patient selection,
they also observed a loss of EGFRvIII expression in the
non-vaccinated placebo plus standard of care group [47],
which is in line with the observations of van den Bent et al.
In addition to the prognostic value of EGFRvIII, our
observation that EGFRvIII expression and MAPK activation
result in an increased MMR and therefore TMZ sensitivity,
may be of direct clinical relevance because current clinical
trials are testing the combination of TMZ with EGFR/
EGFRvIII or MAPK targeting approaches or are assessing
new EGFRvIII-specific treatment approaches in recurrent
GBM (NCT02573324, NCT02364206, NCT03283631).
Our data indicate that such combinations may lead to TMZ
resistance due to decreased MMR protein expression, or that
recurrent GBM might have lost their EGFRvIII expression
after initial standard of care treatment. Therefore, anti-
EGFRvIII and anti-MAPK strategies should be used very
cautiously when combined with TMZ. This finding might
also help explain the failure of the EGFR and EGFRvIII
targeting trials published so far [48, 49].
In contrast to TMZ sensitivity, radiotherapy outcomes
seem to be unaffected by EGFRvIII, because i) we observed
no differences in patient survival between the EGFRvIII+
and EGFRvIII− group for MGMT-U tumors where TMZ is
of less relevance, ii) former clinical trials published before the
implementation of TMZ, but including irradiation, showed no
survival differences with regard to EGFRvIII expression
(table S1) and iii) our previous preclinical data demonstrated
no impact of EGFRvIII on cellular radiosensitivity [20].
Altogether, our data strongly suggest that MGMT pro-
moter methylation and EGFRvIII are two closely linked
biomarkers predicting the outcome under standard of care
treatment; together they identify tumors with increased TMZ
sensitivity and best prognosis as summarized in Fig. 6. Since
approximately 13% of GBM are MGMT-M/EGFRvIII+
tumors, based on the three analyzed cohorts, EGFRvIII
positivity together with MGMT promoter methylation status
might be considered as relevant factors, e.g. for patient
stratification in future clinical trials. Furthermore, our results
highlight that oncogenes, such as EGFRvIII, do not always
mediate resistance against radio- or chemotherapy. By
upregulating certain DNA repair pathways such as MMR,
they can also generate a specific and targetable Achilles´
heel in some tumors that may be further explored in future
personalized therapies. With regard to EGFRvIII this might
not only be of relevance for adult GBM but also for other
tumor entities, such as pediatric brain tumors and ovarian
cancers, which also show EGFRvIII expression [50, 51].
Materials and methods
Patient survival analysis
Data from 336 GBM patients with IDH1 wild type tumors
and known MGMT promoter methylation, EGFRvIII, EGFR
amplification, and IDH1 status were included in the analysis.
IDH2 mutations were no exclusion criteria since these are
rare events in GBM. Patients had all been treated with
standard of care, comprised of radiotherapy with concurrent
temozolomide, followed by temozolomide alone. Recurrent
resection was an exclusion criteria. Survival analysis was
performed using the ‘survival’ and ‘survminer’ packages in
the R statistical software suite with analysis on overall
Fig. 5 Impact of MAPK signaling on MMR protein expression. a
Detection of EGFR, EGFRvIII, ERK1/2, pERK1/2 (T202/Y204) by
western blot analysis. β-actin served as loading control. Samples were
normalized to cell number. b Impact of siRNA mediated ERK1/2
knockdown in BS153vIII+ cells on MLH1, MSH2, and MSH6
expression after 24, 48, and 72 h. An siRNA against cyclophilin B
served as a control. Western blot analysis, β-actin served as a control.
For quantification of relative MMR protein expression protein levels
were normalized to β-actin and to MLH1, MSH2, and MSH6 levels in
the control. c–f Functional kinome profiling. c Detection of sequence-
specific peptide phosphorylation on STK-PamChip® using anti-phos-
pho-Ser/Thr antibodies (cycle: 124; exposure time: 100 ms). d Heat-
map showing log2-transformed signal intensities for the
phosphorylated peptides. The signals were sorted from high (red) to
low (blue) intensity/phosphorylation. e Two-group comparison of
EGFRvIII+ vs. EGFRvIII− depicted as a volcano plot (effect size > 0:
higher phosphorylation in EGFRvIII+; significance score > 1.3 indi-
cates significant changes, dotted line). f Upstream kinase analysis of
EGFRvIII+ vs. EGFRvIII−; top 20 of the differentially regulated
kinases (Normalized kinase statistic > 0: higher kinase activity in
EGFRvIII+; specificity score > 1.3 (white to red bars): statistically
significant changes). g Detection of EGFR, pEGFR (Y1173), p38,
pp38 (T180/Y182), JNK and pJNK (T183/Y185) by western blot
analysis. β-actin served as loading control. Samples were normalized
to cell number. For quantification of relative JNK and p38 phos-
phorylation, relative phosphorylation values of EGFRvIII+ cells were
normalized to the relative values of EGFRvIII− cells (mean with S.E.
M, n= 3; P-values are obtained by one-tailed Student’s t test, *p <
0.05). h Impact of siRNA-mediated p38 knockdown in BS153vIII+
cells on MLH1, MSH2 and MSH6 expression after 24, 48, and 72 h.
An siRNA against cyclophilin B served as a control. β-actin served as
loading control. For quantification of relative MMR protein expression
protein levels were normalized to β-actin and to MLH1, MSH2 and
MSH6 levels in the control.
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survival in days. The significance of the separation of
Kaplan–Meier survival curves, based on EGFRvIII status,
was calculated using a log-rank test. The data originated
from three independent cohorts, herein referred to as the
University of Pennsylvania (UPenn [28]) cohort (230 cases),
the North Bristol NHS Trust (Bristol [18]) cohort (29 cases)
and the TCGA cohort (79 cases, extracted from the Brennan
et al. publication [29]).
University of Pennsylvania patient cohort
GBM Patients undergoing surgical resection for a cranial
malignancy were identified through the University of
Pennsylvania’s Center for Personalized Diagnostics (CPD).
Exclusion criteria were IDH1 mutation, 1p19q co-deletion,
recurrent resection, and missing EGFRvIII or MGMT pro-
moter methylation status [28, 52]. For the UPenn cohort
IDH1 status was obtained by both IHC staining and con-
firmatory next generation sequencing (NGS). All UPenn
patient data were obtained retrospectively under a protocol
approved by the University of Pennsylvania’s Institutional
Review Board, with a waiver for patient consent.
North Bristol NHS Trust
GBM patients were tested for EGFR amplification by
fluorescence in situ hybridization (FISH) and
immunohistochemistry, whereas EGFRvIII expression was
detected by reverse-transcription PCR and immunohis-
tochemistry [18]. While known MGMT promoter methy-
lation, EGFRvIII, EGFR amplification were inclusion
criteria, exclusion criteria were IDH1 mutation, 1p19q co-
deletion, recurrent resection, and missing EGFRvIII or
MGMT promoter methylation status. MGMT promoter
methylation analysis was carried out by bisulphite conver-
sion and pyrosequencing using primers as described by
Dunn et al. [53]. IDH mutation status was performed by
immunohistochemistry for the R132H mutation.
In terms of the Bristol patients, samples were obtained
from the Brain Tumour Bank South West (BRASH) at
North Bristol NHS Trust UK under approval of Research
Ethics Committee for Wales with a waiver for patient
consent.
TCGA Cohort
GBM patient data were extracted from the Brennan et al.
publication [29]. For the TCGA cohort IDH status was
obtained by NGS or Sanger-based sequencing.
GBM patient samples
Human tumor material was used in accordance with all local
and national ethics guidelines.
Fig. 6 Model. Under conditions where MGMT is expressed (MGMT-
U), both EGFRvIII- and EGFRvIII+ GBM cells are resistant to TMZ.
This is because MGMT removes the O6MeG lesions and therefore
prevents replication-dependent induction of DNA DSB. EGFRvIII−
cells which do not express MGMT (MGMT-M) display moderate TMZ
sensitivity, because O6MeG lesions are converted through futile MMR
cycles into DSB. In MGMT deficient (MGMT-M) cells expressing
EGFRvIII, MAPK signaling is activated, which leads to upregulation
of MMR protein expression. This leads to a more efficient conversion
of O6MeG lesions into lethal DSB and, consequently, to increased
TMZ sensitivity.
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Cell culture
The human GBM cell lines DKMGvIII−/+ and BS153vIII
−/+ were generated and characterized as described pre-
viously [20]. All cells were identified by a short tandem
repeat multiplex assay (Applied Biosystems).
Xenografts
Nine-week old female BALB/c nude mice (BALB/
cAnNCrl-Foxn1<nu>) were obtained from Charles River
UK. 2 × 105 BS153vIII−/+ cells in 2 µl DMEM were
injected into the right frontal lobe of each animal using a
stereotactic frame. Mice were randomly assigned to
experimental groups (10 mice/group) for treatment, which
commenced two weeks after the surgery. TMZ was admi-
nistered by intraperitoneal (IP) injection at 5 mg/kg/day in
10% DMSO for five consecutive days. Control animals
received 10% DMSO in PBS, IP, following the same
schedule. Animal welfare was monitored and documented
daily and mice were euthanized when they exhibited neu-
rological symptoms and/or substantial weight loss (max-
imum tolerated loss was 20% of body mass). Animals were
culled by perfusion/fixation (4% paraformaldehyde; PFA)
under terminal anaesthesia. All work was performed in
accordance with the United Kingdom Animals (Scientific
Procedures) Act (1986), under the authority of project
licence 70/7340. Kaplan–Meier curves were generated in
GraphPad Prism and statistical analysis of survival was
generated automatically by the software using log-rank test.
Reagents
Temozolomide (stock concentration: 100 mM, Sigma-
Aldrich) was dissolved in DMSO (Sigma-Aldrich) and
stored at −20 °C. Staurosporine (stock concentration:
1 mM, Sigma-Aldrich), stored at −20 °C.
PCR MGMT promoter methylation
MGMT promoter methylation was determined by
methylation-specific PCR (MSP). The isolation of nucleic
acids, bisulphite modification of DNA and methylation-
specific PCR (MSP) were performed following standard
laboratory protocols and using commercially available kits
performed according to the manufacturer’s protocols.
Colony forming assay
To analyze the ability of GBM cells for self-renewal (clo-
nogenicity) 200–350 cells were seeded 24 h prior to treat-
ment with TMZ. After 24 h of treatment the medium was
replaced by AmnioMax C-100 containing 10% FCS and
C-100 supplement (Life Technologies) to allow proper
colony formation. All cells were cultured at 37 °C, 5% CO2
and 100% humidification for colony growth. The cells were
grown until the colonies of all treatment arms had reached
equal colony size (approximately 14–28 d). The cells were
fixed, stained and colonies of more than 50 cells were
counted manually. The surviving fraction of treated cells
was normalized to the plating efficiency of non-treated cells.
siRNA mediated knockdown
Knockdown of EGFRvIII, MLH1, MSH6, ERK1/2, and
p38 was performed using HiPerFect (Qiagen, #301705)
according to the manufacturer´s instructions. The following
siRNAs were used: EGFRvIII from Eurofins Scientific;
[5´-CUGGAGGAAAAGAAAGGUAAU-3´]; MLH1 and
MSH6 (Ambion, #AM51331; #AM1678); ERK1/2 siRNA
(Cell Signaling, #6560), p38 siRNA (Cell Signaling,
#6243). On-Target plus Cyclophilin B control pool as
control siRNA (Dharmacon, #SO-2436533G). The medium
was changed 5 h after transfection and 24 h later the colony
forming assay was performed as described below.
Western blot
Proteins from whole-cell extracts were detected by Western
blot according to standard protocols. The Odyssey® CLx
Infrared Imaging System (LI-COR Biosciences) was used
for signal detection and quantification. Primary antibodies:
EGFR (1:1000, rabbit, Cell Signaling, #2232); pEGFR
(1:1000, rabbit, Cell Signaling, #4407); β-Actin (1:20,000,
mouse, Sigma-Aldrich, #A-2228); MLH1 (1:1000, Cell
Signaling, #3515); MSH2 (1:1000, Cell Signaling, #2850);
MSH6 (1:1000, Cell Signaling, #4407); MSH3 (1:1000, BD
Transduction Laboratories, #611390); PMS2 (1:1000,
Rockland, #29379); PCNA (1:1000, Santa Cruz Bio-
technology, sc-56); ERK1/2 (1:1000. Cell Signaling,
#9107); pERK1/2 (1:1000. Cell Signaling, #4370); p38
(1:1000, Cell Signaling, #8690); pp38 (1:1000, Cell Sig-
naling, #4511); JNK (1:1000. Cell Signaling, #9252), pJNK
(1:1000. BD Transduction Laboratories, #612540). All
primary antibodies were diluted in 5% bovine serum albu-
mine (BSA) in PBS supplemented with 0.2% Tween. Sec-
ondary anti-mouse and anti-rabbit antibodies were
purchased from LI-COR Biosciences.
Flow cytometry
Flow cytometry was performed as described previously
using a FACSCanto and FACSDiva software (BD Bios-
ciences) [20, 54]. For EGFRvIII detection and quantifica-
tion anti-EGFRvIII antibody L8A4 (1:1000, mouse,
Absolute antibody, #Ab00184-1.4) and Alexa fluor® 647
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labeled secondary antibody (1:1000, Life Technologies,
#A-21235) were usd. Cell-surface exposure of phosphati-
dylserine was assessed using an Annexin-V-FITC conjugate
following the manufacturer’s instructions (Thermo Scien-
tific, #A13199). For cell cycle analysis via propidium iodid
staining the fraction of G1, S, and G2 phase cells was
calculated using ModFit LT™ software (Verity Software
House, Inc.).
Immunofluorescence staining
EGFRvIII specific immunofluorescence was performed as
reported earlier [20]. For DNA repair analysis cells were
fixed, blocked and stained with the anti-53BP1 (1:1000,
Novus, Biologicals, #NB-100-3004) and γH2AX (1:500,
MerckMilipore, #05-636) antibody and the respective sec-
ondary antibodies (ALEXA fluor® 488; ALEXA fluor® 594,
1:1000, Life Technologies, #A-11001; A-11005) at RT for
60 min; DNA was then stained with 4′,6-diamidino-2-phe-
nylindole (DAPI; QBiogene). A confocal fluorescence
microscope (Zeiss Axio Observer Z1; 630x magnification)
was used for analysis. At least 100 intact nuclei were ran-
domly selected and γH2AX/53BP1 double positive foci
were counted. Z-stacks of semi-confocal images were
obtained using the Zeiss Apotome, Zeiss AxioCam MRm
and Zeiss AxioVision Software and 53BP1 foci were
counted using ImageJ.
Immunohistochemistry
Five-micrometer sections of paraffin-embedded GBM spe-
cimens were dewaxed using standard histologic procedures.
Heat-induced antigen retrieval for the detection of MSH2
(1:1000; rabbit, Abcam #ab72070) and MSH6 (1:250;
mouse, Dako, #3646) was carried out by boiling slides in
sodium citrate buffer, pH 6.8, for 1 hour. Primary antibodies
were incubated overnight at 4 °C. Specimens were then
incubated with secondary antibody (Immpress reagent kit
anti-rabbit IgG, Vector Laboratories, #MP7401 or Imm-
press reagent kit anti-mouse IgG, Vector Laboratories,
MP7402) for 1 h. Bound secondary antibody was detected
by ImmPact DAB substrate (Vector Laboratories, #sk-405).
EGFRvIII staining was performed on a Ventana System
using standard protocols (1:250, mouse, Absolute antibody,
#Ab00184-1.4). Nuclei were counterstained with hematox-
ylin. After staining the specimes werde dehydrated covered
using standard histologic procedures.
Kinase activity profiling
Kinase activity profiling has been described previously [40].
Here we used a PamStation®12 (located at the UCCH
Kinomics Core Facility, UKE, Hamburg, Germany)
according to the manufacturer’s instructions (PamGene
International, ´s-Hertogenbosch, The Netherlands). In brief,
whole-cell lysates were made using M-PER Mammalian
Extraction Buffer containing Halt Phosphatase Inhibitor and
EDTA-free Halt Protease Inhibitor Cocktail (Pierce, Wal-
tham, Massachusetts, USA). For profiling serine/threonine
kinases, STK-PamChip® arrays were incubated with 1 μg of
protein and 400 μM ATP per array. Each array contains 140
individual phospho-sites that are peptide sequences derived
from substrates for serine/threonine kinases. Sequence-
specific peptide serine/threonine phosphorylation was detec-
ted in two steps, first with anti-phospho-Ser/Thr antibodies
during the reaction followed by detection with secondary
antibody (polyclonal swine anti-rabbit Immunoglobulin/
FITC, PamGene International). Signals were recorded using
a CCD camera and the Evolve software (PamGene Interna-
tional, ´s-Hertogenbosch, The Netherlands). After quality
control, the final signal intensities were log2-transformed and
were used for further data analysis using the BioNavigator
software version 5.1 (PamGene International, ‘s-Hertogen-
bosch, The Netherlands).
Statistical analysis (pre-clinical data)
Except for tumor cell injection and unless otherwise indi-
cated, experiments were repeated at least three times. The
data are presented as mean values (±SEM) except for the
patient data. Prism software (GraphPad Prism 5, GraphPad
Software, Inc.) was used for analyzing and graphing the
data. P-values were calculated using Student´s t-tests (*p <
0.05; **p < 0.01; ***p < 0.001).
Author contributions NS, MK, SCS, and KR contributed to the design
of the study. NS and MK wrote the paper. All authors participated in
the review of the paper. NS performed colony formation assays, flow
cytometry, western blot analysis, and knockdown experiments. LO
performed cell cycle and DNA repair analysis. JMG, LO, and KH
contributed to western blot analysis. AW and KH performed Annexin
V staining. KH and LB performed kinomic profiling. MK and LB
analyzed kinomic data. AW performed immunohistochemical staining.
LK performed immunofluorescence staining. TR contributed to writ-
ing the paper. CP and MH added valuable impact to the discussion.
U.S. was responsible for determining MGMT promoter methylation
status of the cell lines and provided GBM specimens. MK supervised
the in vitro work. TB performed and analyzed the in vivo work. SCS
supervised the in vivo work. For the UPenn cohort ZAB, SJG, and
DOR provided clinical data and JJD was responsible for determination
of EGFRvIII and MGMT promoter methylation status. CF and KMK
provided the data of the Bristol cohort. LFS performed patient survival
analysis.
Funding This work was supported by the Brigitte and Dr. Konstanze
Wegener-Stiftung (MK), Wilhelm-Sander-Stiftung (MK), For-
schungsförderungsfonds des Fachbereichs Medizin des Uni-
versitätsklinikums Hamburg-Eppendorf (NS) and the Federal Ministry
of Education and Research (BMBF grant 02NUK032; MK, KR),
Cancer Research UK (CRUK/21600; SCS, TB), The Brain Tumour
Charity (TBTC13/192; SCS, TB), Medical Research Council (MR/
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT. . . 3053
K015214/1; SCS, TB), University of Leeds Academic Fellowship
(LFS), The Templeton Family Research Fund (ZAB), The Maria and
Gabriele Troiano Brain Cancer Immunotherapy Fund (ZAB, DOR)
and the National Institutes of Health (NIH 2R01-NS042645-11A1;
DOR). U.S. is supported by the Fördergemeinschaft Kinderkrebs-
Zentrum Hamburg. Open access funding provided by Projekt DEAL.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,
Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. N. Engl J Med. 2005;352:987–96.
2. Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac
V, et al. Long-term survival in glioblastoma: methyl guanine
methyl transferase (MGMT) promoter methylation as independent
favourable prognostic factor. Radiol Oncol. 2016;50:394–401.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N,
Weller M, et al. MGMT gene silencing and benefit from temo-
zolomide in glioblastoma. N. Engl J Med. 2005;352:997–1003.
4. Qi ST, Yu L, Lu YT, Ou YH, Li ZY, Wu LX, et al. IDH mutations
occur frequently in Chinese glioma patients and predict longer
survival but not response to concomitant chemoradiotherapy in
anaplastic gliomas. Oncol. Rep. 2011;26:1479–85.
5. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al.
Isocitrate dehydrogenase 1 codon 132 mutation is an important
prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150–4.
6. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glio-
blastoma multiforme. J Clin. Neurosc. 2009;16:748–54.
7. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA,
Bigner DS, et al. Structural alterations of the epidermal growth
factor receptor gene in human gliomas. Proc Natl Acad Sci USA.
1992;89:2965–9.
8. Boyd PS, Struve N, Bach M, Eberle JP, Gote M, Schock F, et al.
Clustered localization of EGFRvIII in glioblastoma cells as
detected by high precision localization microscopy. Nanoscale.
2016;8:20037–47.
9. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong
RA, et al. EGFR phosphorylates tumor-derived EGFRvIII driving
STAT3/5 and progression in glioblastoma. Cancer Cell.
2013;24:438–49.
10. Zheng Q, Han L, Dong Y, Tian J, Huang W, Liu Z, et al. JAK2/
STAT3 targeted therapy suppresses tumor invasion via disruption
of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion
in EGFRvIII-expressing glioblastoma. Neuro Oncol. 2014;16:
1229–43.
11. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sir-
asanagandala S, Nannepaga S, et al. EGFRvIII and DNA double-
strand break repair: a molecular mechanism for radioresistance in
glioblastoma. Cancer Res. 2009;69:4252–9.
12. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Naka-
mura H, et al. Prognostic value of epidermal growth factor
receptor in patients with glioblastoma multiforme. Cancer Res.
2003;63:6962–70.
13. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B,
et al. Oncogenic EGFR signaling activates an mTORC2-NF-
kappaB pathway that promotes chemotherapy resistance. Cancer
Discov. 2011;1:524–38.
14. Bienkowski M, Piaskowski S, Stoczynska-Fidelus E, Szybka M,
Banaszczyk M, Witusik-Perkowska M, et al. Screening for EGFR
amplifications with a novel method and their significance for the
outcome of glioblastoma patients. PLoS ONE 2013;8:e65444.
15. Montano N, Cenci T, Martini M, D’Alessandris QG, Pelacchi F,
Ricci-Vitiani L, et al. Expression of EGFRvIII in glioblastoma:
prognostic significance revisited. Neoplasia. 2011;13:1113–21.
16. Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D,
Pietsch T, et al. Assessment and prognostic significance of the
epidermal growth factor receptor vIII mutation in glioblastoma
patients treated with concurrent and adjuvant temozolomide
radiochemotherapy. Int J Cancer. 2014;134:2437–47.
17. Cominelli M, Grisanti S, Mazzoleni S, Branca C, Buttolo L,
Furlan D, et al. EGFR amplified and overexpressing glioblastomas
and association with better response to adjuvant metronomic
temozolomide. J Natl Cancer Inst. 2015;107:djv041.
18. Faulkner C, Palmer A, Williams H, Wragg C, Haynes HR, White
P, et al. EGFR and EGFRvIII analysis in glioblastoma as ther-
apeutic biomarkers. Br J Neurosurg. 2014;29:23–9.
19. Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A,
Malzkorn B, et al. Epidermal growth factor receptor variant III
(EGFRvIII) positivity in EGFR-amplified glioblastomas: prog-
nostic role and comparison between primary and recurrent tumors.
Clin. Cancer Res. 2017;23:6846–55.
20. Struve N, Riedel M, Schulte A, Rieckmann T, Grob TJ, Gal A, et al.
EGFRvIII does not affect radiosensitivity with or without gefitinib
treatment in glioblastoma cells. Oncotarget. 2015;6:33867–77.
21. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert
M, et al. Prognostic effect of epidermal growth factor receptor and
EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res.
2005;11:1462–6.
22. Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike
HM, et al. Clinical significance of EGFR amplification and the
aberrant EGFRvIII transcript in conventionally treated astrocytic
gliomas. J Mol Med. 2005;83:917–26.
23. Riedel M, Struve N, Muller-Goebel J, Kocher S, Petersen C,
Dikomey E, et al. Sorafenib inhibits cell growth but fails to
enhance radio- and chemosensitivity of glioblastoma cell lines.
Oncotarget. 2016;7:61988–95.
24. O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mans-
field K, Morrissette JJD, et al. A single dose of peripherally
infused EGFRvIII-directed CAR T cells mediates antigen loss
and induces adaptive resistance in patients with recurrent glio-
blastoma. Sci Trans Med. 2017;9:eaaa0984. https://doi.org/10.
1126/scitranslmed.aaa0984.
25. Reardon DA, Lassman AB, van den Bent M, Kumthekar P,
Merrell R, Scott AM, et al. Efficacy and safety results of ABT-414
in combination with radiation and temozolomide in newly diag-
nosed glioblastoma. Neuro Oncol. 2017;19:965–75.
26. van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R,
Butowski N, et al. Efficacy of depatuxizumab mafodotin (ABT-
3054 N. Struve et al.
414) monotherapy in patients with EGFR-amplified, recurrent
glioblastoma: results from a multi-center, international study.
Cancer Chemother Pharmacol. 2017;80:1209–17.
27. Weller M, Butowski NA, Tran DD, Recht LD, O´Rourke DM,
Finocchiaro G, et al. ACTIV: an international, double-blind, phase
3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing
glioblastoma. Neuro Oncol. 2017;19:1373–85.
28. Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H,
et al. Epidermal growth factor receptor extracellular domain
mutations in glioblastoma present opportunities for clinical imaging
and therapeutic development. Cancer Cell 2018;34:163–77 e7.
29. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr
H, Salama SR, et al. The somatic genomic landscape of glio-
blastoma. Cell 2013;155:462–77.
30. van den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, van
Zwieten K, et al. Changes in the EGFR amplification and
EGFRvIII expression between paired primary and recurrent glio-
blastomas. Neuro Oncol. 2015;17:935–41.
31. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW.
The neuropharmacokinetics of temozolomide in patients with
resectable brain tumors: potential implications for the current
approach to chemoradiation. Clin Cancer Res. 2009;15:7092–8.
32. Kaina B, Christmann M. DNA repair in resistance to alkylating
anticancer drugs. Int J Clin Pharmacol Ther. 2002;40:354–67.
33. Kaina B, Ochs K, Grosch S, Fritz G, Lips J, Tomicic M, et al.
BER, MGMT, and MMR in defense against alkylation-induced
genotoxicity and apoptosis. Prog Nucleic Acid Res Mol Biol.
2001;68:41–54.
34. D’Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E,
et al. Involvement of the mismatch repair system in temozolomide-
induced apoptosis. Mol Pharmacol. 1998;54:334–41.
35. Dosch J, Christmann M, Kaina B. Mismatch G-T binding activity
and MSH2 expression is quantitatively related to sensitivity of
cells to methylating agents. Carcinogenesis. 1998;19:567–73.
36. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO.
Early Chk1 phosphorylation is driven by temozolomide-induced,
DNA double strand break- and mismatch repair-independent DNA
damage. PLoS ONE 2013;8:e62351.
37. McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato
P, Sangaraju D, et al. Minor changes in expression of the mismatch
repair protein MSH2 exert a major impact on glioblastoma response
to temozolomide. Cancer Res. 2015;75:3127–38.
38. Mojas N, Lopes M, Jiricny J. Mismatch repair-dependent processing
of methylation damage gives rise to persistent single-stranded gaps in
newly replicated DNA. Genes Dev. 2007;21:3342–55.
39. Quiros S, Roos WP, Kaina B Processing of O6-methylguanine
into DNA double-strand breaks requires two rounds of replication
whereas apoptosis is also induced in subsequent cell cycles. Cell
Cycle. 2010;9:168–78.
40. Arni S, Le THN, de Wijn R, Garcia-Villegas R, Dankers M,
Weder W, et al. Ex vivo multiplex profiling of protein tyrosine
kinase activities in early stages of human lung adenocarcinoma.
Oncotarget. 2017;8:68599–613.
41. Lei X, Zhu Y, Tomkinson A, Sun L. Measurement of DNA mis-
match repair activity in live cells. Nucleic Acids Res. 2004;32:e100.
42. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC,
Westphal M, et al. Promoter methylation and expression of
MGMT and the DNA mismatch repair genes MLH1, MSH2,
MSH6 and PMS2 in paired primary and recurrent glioblastomas.
Int J Cancer. 2011;129:659–70.
43. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, et al.
MSH6 mutations arise in glioblastomas during temozolomide
therapy and mediate temozolomide resistance. Clin Cancer Res:
Off J Am Assoc Cancer Res. 2009;15:4622–9.
44. Wachsberger PR, Lawrence RY, Liu Y, Rice B, Daskalakis C,
Dicker AP. Epidermal growth factor receptor mutation status and
rad51 determine the response of glioblastoma to multimodality
therapy with cetuximab, temozolomide, and radiation. Front
Oncol. 2013;3:13.
45. Gazzoli I, Kolodner RD. Regulation of the human MSH6 gene by
the Sp1 transcription factor and alteration of promoter activity and
expression by polymorphisms. Mol Cell Biol. 2003;23:7992–8007.
46. Scherer SJ, Maier SM, Seifert M, Hanselmann RG, Zang KD,
Muller-Hermelink HK, et al. p53 and c-Jun functionally synergize
in the regulation of the DNA repair gene hMSH2 in response to
UV. J Biol Chem. 2000;275:37469–73.
47. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H,
et al. Rindopepimut with temozolomide for patients with newly
diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a ran-
domised, double-blind, international phase 3 trial. Lancet Oncol.
2017;18:1373–85.
48. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm
JH, et al. Phase I/II trial of erlotinib and temozolomide with
radiation therapy in the treatment of newly diagnosed glio-
blastoma multiforme: North Central Cancer Treatment Group
Study N0177. J Clin Oncol. 2008;26:5603–9.
49. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agar-
wal N, Stevens GH, et al. Phase II trial of erlotinib with temo-
zolomide and radiation in patients with newly diagnosed
glioblastoma multiforme. J Neuro-oncol. 2010;98:93–9.
50. Li G, Mitra SS, Monje M, Henrich KN, Bangs CD, Nitta RT, et al.
Expression of epidermal growth factor variant III (EGFRvIII) in
pediatric diffuse intrinsic pontine gliomas. J neuro-Oncol.
2012;108:395–402.
51. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G,
Gunn G, Zoltick PW, et al. Frequent expression of a mutant
epidermal growth factor receptor in multiple human tumors.
Cancer Res. 1995;55:5536–9.
52. Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB,
Roth JJ, et al. Molecular Neuropathology in Practice: Clinical
Profiling and Integrative Analysis of Molecular Alterations in
Glioblastoma. Academic Pathol. 2019;6:2374289519848353.
53. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al.
Extent of MGMT promoter methylation correlates with outcome
in glioblastomas given temozolomide and radiotherapy. Br J
Cancer. 2009;101:124–31.
54. Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R,
et al. Radiosensitization of NSCLC cells by EGFR inhibition is
the result of an enhanced p53-dependent G1 arrest. Radiother
Oncol. 2015;115:120–7.
EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT. . . 3055
